EMA Committee Urges Warning About Hep B Reactivation In Patients Taking DAAs
Executive Summary
The European Medicines Agency’s pharmacovigilance committee wants manufacturers of the direct-acting antivirals for hepatitis C to include a warning about the possibility of hepatitis B reactivation in patients who carry both viruses.
You may also be interested in...
Direct-Acting Antivirals Slapped With Black Box On Hepatitis B Risk
FDA imposes boxed warning on labels for hepatitis C drugs in response to reports of hepatitis B reactivation, including fatal cases.
Labeling Changes Possible For HCV Direct-Acting Antivirals As EMA Probes HBV Reactivation
The European Medicines Agency has begun a review of the direct-acting antivirals (DAAs) for hepatitis C in light of a number of recent cases showing that hepatitis B virus has been reactivated in some HCV patients treated with the newer products1.
Austria & Germany Call For ‘Competitiveness Check’ On EU Pharma Revision Package
The two countries want the European Commission’s proposals to be more closely examined for their possible negative effect on pharmaceutical investment decisions. The industry federation EFPIA says it is surprised more EU member states aren’t taking the same stance.